Get the Stockscreener App
29.80
0.80%
-0.24
Alkermes Plc stock is traded at $29.80, with a volume of 2.08M.
It is down -0.80% in the last 24 hours and up +7.16% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$30.04
Open:
$30.3
24h Volume:
2.08M
Relative Volume:
1.06
Market Cap:
$4.92B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.28
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-1.52%
1M Performance:
+7.16%
6M Performance:
+7.70%
1Y Performance:
+10.99%
1-Day Range:
$29.53
$30.51
1-Week Range:
$29.53
$32.02
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
29.80 | 4.96B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
145.94 | 64.88B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.01 | 44.40B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.25 | 41.72B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.82B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
418.58 | 19.28B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
What recovery options are there for Alkermes plcWeekly Market Report & Safe Entry Point Alerts - newser.com
Real time social sentiment graph for Alkermes plcAnalyst Upgrade & Capital Efficient Trading Techniques - newser.com
3 Biopharma Names I Am Buying After Avadel's Buyout - Seeking Alpha
Why Alkermes plc stock appeals to analysts2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Is Alkermes plc (8AK) stock at risk of policy regulation2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Order flow analysis tools used on Alkermes plcMarket Growth Summary & AI Optimized Trade Strategies - newser.com
Can Alkermes plc stock maintain growth trajectory2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
Price momentum metrics for Alkermes plc explainedJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com
Can Alkermes plc stock deliver consistent earnings growthWeekly Risk Report & AI Forecast Swing Trade Picks - newser.com
Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio - Sleep Review
Is Alkermes plc forming a bottoming baseTrade Risk Summary & Weekly High Return Stock Opportunities - newser.com
Deal Dispatch: Four Roses, Quantum Computing, Travis KelceAir France (OTC:AFLYY), Alkermes (NASDAQ:ALKS) - Benzinga
Biotech M&A Action Gets Another Jolt With $2 Billion Avadel-Alkermes Deal - TheStreet Pro
Alkermes Plc expected to post earnings of 30 cents a shareEarnings Preview - TradingView
Published on: 2025-10-24 02:21:47 - newser.com
Published on: 2025-10-23 22:46:36 - newser.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Oct 15 '25 |
Sale |
31.53 |
9,000 |
283,776 |
73,740 |
0.60%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):